Evommune (EVMN) EBITDA (2024 - 2026)

Evommune (EVMN) has reported EBITDA for 3 consecutive years, with -$24.0 million the latest figure, recorded in Q1 2026.

• In Q1 2026, EBITDA fell 59.35% year-over-year to -$24.0 million; the TTM figure through Mar 2026 stood at -$82.0 million (changed N/A YoY), while the FY2025 annual figure was -$81.1 million, down 15.79% from the prior year.
• EBITDA grew to -$24.0 million in Q1 2026 per EVMN's latest filing, from -$29.7 million in the prior quarter.
• Across five years, EBITDA topped out at -$13.3 million in Q3 2025 and bottomed at -$29.7 million in Q4 2025.
• Historically, EBITDA has averaged -$20.0 million across 3 years, with a median of -$19.0 million in 2024.
• Annual changes were most pronounced in 2025 — EBITDA climbed 19.31% — and 2026, when it plunged 59.35%.
• Evommune's EBITDA stood at -$21.5 million in 2024, then plunged by 38.51% to -$29.7 million in 2025, then advanced by 19.39% to -$24.0 million in 2026.
• Business Quant data shows EVMN's EBITDA at -$24.0 million in Q1 2026, -$29.7 million in Q4 2025, and -$13.3 million in Q3 2025.